Bespoke Extracts, Inc. (BSPK) Fair Value 2026

BSPK · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.5 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (7/100)

Quick Summary — As of 2026-08-27, Bespoke Extracts, Inc. (BSPK) trades at $0.00. QOC: 4.5/10. Value Trap Risk: 7/100 (SAFE). 1/13 models active.

Key Facts

Ticker
BSPK
Price
$0.00
Quality Score
4.5/10
Value Trap Risk
7/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +291.5% upside with 28% confidence
Risk: Below-average Quality Score of 4.5/10 signals weak fundamentals

What Fair Value Does Each Model Give BSPK?

1 Intrinsic Value Models vs. Current Price ($0.00)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.00 +291.5%

All Models Active

All 1 models are displayed above.

What Is Bespoke Extracts, Inc. (BSPK) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Bespoke Extracts, Inc.'s intrinsic value is estimated at a median fair value of $0.00. At a current market price of $0.00, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +291.5%.

What Do the Models Say About BSPK?

1 of 13 models are currently active for BSPK. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does BSPK Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, BSPK ranks #91 by Quality of Company score. CirclFi's QOC score of 4.5/10 evaluates 32 fundamental signals. A score of 4.5 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Bespoke Extracts, Inc.'s positioning within the Drug Manufacturers - Specialty & Generic segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.

Is BSPK a Value Trap?

CirclFi's Value Trap algorithm assigns BSPK a score of 7/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Bespoke Extracts, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Bespoke Extracts, Inc. earns a quality score of 4.5/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BSPK valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BSPK's 1 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Bespoke Extracts, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

CPHIChina Pharma Holdings, Inc.QOC 4.6CTORCitius Oncology, Inc.QOC 4.4RAPHRaphael Pharmaceutical Inc.QOC 4.6KOANResonate Blends, Inc.QOC 4.4CPMDCannaPharmaRX, Inc.QOC 4.6CBIHCannabis Bioscience International Holdings, Inc.QOC 4.3RDYDr. Reddy's Laboratories LimitedQOC 8.8ANIKAnika Therapeutics, Inc.QOC 6.8CBDYTarget Group Inc.QOC 5.8UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: CPHI · CTOR · RAPH · KOAN · CPMD · CBIH · RDY · ANIK · CBDY · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to BSPK?

7 companies across all industries closest to BSPK’s Quality of Company score of 4.5/10.

RMTRoyce Micro-Cap Trust, Inc.QOC 4.5GPOXGPO Plus, Inc.QOC 4.5MYSEMyseum.AI, Inc.QOC 4.5HINDVyome Holdings, Inc.QOC 4.5QSQuantumScape CorporationQOC 4.5STEKStemtech CorporationQOC 4.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RMT · GPOX · MYSE · HIND · QS · STEK · NVDA

Where Does BSPK Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

BSPK is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Bespoke Extracts, Inc.’s Valuation?

What is Bespoke Extracts, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Bespoke Extracts, Inc. (BSPK). The Quality of Company score is 4.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BSPK overvalued or undervalued right now?

At $0.00, 1 of 1 active models suggest BSPK may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Bespoke Extracts, Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 4.5 mean for BSPK?

Bespoke Extracts, Inc.'s QOC of 4.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on BSPK?

CirclFi analyzes BSPK with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is BSPK a value trap in 2026?

Bespoke Extracts, Inc.'s Value Trap score is 7/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Bespoke Extracts, Inc. (BSPK) a Quality of Company score of 4.5/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/BSPK/ · Methodology
Primary sources for this BSPK valuation
  • Financial statements: Bespoke Extracts, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001409197) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BSPK as of ; valuations recomputed .